NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Okay. Are you following? NWBO (assignee) has a joint patent application with UCLA (assignee) and Revimmune (assignee) and NIH/NCI (assignee, assigned by NWBO)

The combination trial with DCVax-l, Poly-ICLC and Keytruda has the following sponsors.

Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Phase One Foundation
Oncovir, Inc.

The combination patent application is temporarily abandoned, but, according to your buddy Exwannabe, whom I believe in this case, NWBO filed a timely continuation.

Do you know one of the reasons these assignments occur? Because of prior agreements between the parties. Do you know who is pursuing the patent? NWBO. Do you know why the other parties allow NWBO to pursue the patent? Because of prior agreements.

When the combination trial began, it was an outcome of joint effort resulting in a joint patent application.

LP is an expert in intellectual property. You, are not.